echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The clinical application of Boan Bio-Navulumab injection was accepted

    The clinical application of Boan Bio-Navulumab injection was accepted

    • Last Update: 2021-03-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Luye Pharmaceutical Group announced that the clinical trial application for nivolumab injection (LY01015) developed by its subsidiary Boan Biotechnology has been accepted by the Drug Evaluation Center of the National Medical Products Administration.


    LY01015 is the first biosimilar of Opdivo® (Odivo®) declared in accordance with the 3.


    Tumor immunotherapy represented by PD-1 inhibitors has become one of the main methods of cancer treatment in China and even globally.


    As the world's first PD-1 immune checkpoint inhibitor approved by regulatory agencies, nivolumab injection has become an important choice for the treatment of a variety of tumors, and has been approved for more than a dozen indications worldwide.


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.